YOU ARE ABOUT TO EXIT A US HEMANEXT CORPORATE WEBSITE FOR A GLOBAL HEMANEXT ONE PRODUCT WEBSITE
Please be aware that the website you have requested is intended for the residents of countries in the European Union. The site may contain information on products or uses of those products that are not cleared, approved, or otherwise authorized in all countries or regions, including the US Food & Drug Administration.
WITH DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?
On January 24, 2022, Hemanext announced that its innovative blood processing and storage system has been recognized by the Association for the Advancement of Blood & Biotherapies (“AABB”), a leading international association in transfusion medicine and...
On April 13, 2021, Hemanext announced that it had received CE Mark certification for Hemanext ONE® system, clearing the way for the medical device to be sold in European markets. On December 30, 2021, Hemanext submitted the Hemanext ONE® system for marketing...
In 2019, Hemanext and its research colleagues wrote the latest in a series of papers published in prestigious journals that added to the body of scientific evidence supporting the clinical potential of hypoxic RBC storage.
In 2017, NIH awarded another $3 million grant to further develop the Hemanext ONE® RBC Processing and Storage System; the company also completed research that became the pivotal clinical study for obtaining CE Mark certification.